findmyKOL

John Chan, MD

Enriched profile

Division Director of Gynecologic Oncology; Denise & Prentis Cobb Hale Endowed Chair · California Pacific Medical Center

ORCIDNPI
Region🇺🇸 San Francisco, CA · West · United StatesSpecialtyGynecologic OncologyFocusOvarian / Gynecologic Cancer
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2008–2009

John Chan is Division Director of Gynecologic Oncology; Denise & Prentis Cobb Hale Endowed Chair at California Pacific Medical Center. OpenAlex indexes 232 publications with 16,188 citations (h-index 52); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Gynecologic Oncology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

John K. Chan, MD, is Division Director of Gynecologic Oncology at California Pacific Medical Center / Sutter Health (Palo Alto Medical Foundation). The public record shows 232 publications with 16,188 citations (h-index 52), centered on Ovarian / Gynecologic Cancer. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 21 companies, 1 NIH-funded awards (2008–2009).

  • Most recent indexed publication: 2026 · Blood
  • Top research focus: Ovarian / Gynecologic Cancer
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 21 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer4 trialsCarcinoma, Endometrioid3 trialsFallopian Tube Neoplasms2 trialsCarcinoma, Transitional Cell2 trialsBrenner Tumor2 trialsAdenocarcinoma, Mucinous2 trialsAdenocarcinoma, Clear Cell2 trialsFibroma1 trialCoronary Artery Disease / ACS1 trialCoronary Artery Disease1 trialMitral Valve Insufficiency1 trialCarcinoma, Ovarian Epithelial1 trialCarcinoma, Squamous Cell1 trialCarcinoma, Adenosquamous1 trialSarcoma1 trialComa1 trialCarcinosarcoma1 trial

Research focus

OpenAlex concept fingerprint
Ovarian / Gynecologic Cancer

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trialsIndustry payments223PublicationsZejulageneric · NiraparibClinical trialsIndustry payments164PublicationsLenvimageneric · LenvatinibClinical trialsIndustry payments142Publications

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trialsIndustry payments296AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments227Eisai Inc.Clinical trialsIndustry payments141

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
232publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

16,188citations

Total citations across indexed works.

52h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
21companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2008–2009

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    52.2%
    Opioid Agonist52.2%
    Hydrocodone-Acetaminophen100%
    Part D12 patients
  • Cancer & immunology

    47.8%
    Aromatase Inhibitor47.8%
    Letrozole100%
    Part D<11 patients
Where care is delivered (Part B)2.1% facility · 97.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

1 NIH research award on record, funded 20082009 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    University of California, Los Angeles (UCLA) School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sutterhealth.org
  • Fellowship in Gynecologic Oncology

    University of California, Irvine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertperspectives.com
  • Felix Rutledge Fellowship

    MD Anderson Cancer Center, University of Texas

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertperspectives.com
  • Board Certified

    Obstetrics and Gynecology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sutterhealth.org
  • Board Certified

    Gynecologic Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sutterhealth.org

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
  • Medical expert contributor

    SurvivorNet (multiple articles/videos on PARP inhibitors and ovarian cancer treatment)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →survivornet.com
  • Contributing author

    Targeted Oncology (immunotherapy, biomarkers, gynecologic cancer coverage)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.